Daiichi Sankyo Collaborates with LYSA-LYSARC-CALYM for Valemetostat in Patients with R/R B-Cell Lymphoma
Shots:
- LYSA-LYSARC to conduct a P-II study to evaluate the safety and efficacy of valemetostat in six cohorts of patients with r/r B-cell lymphoma. The study will include ~140 patients at 22 sites in France and Belgium and is anticipated to be initiated in 2021
- The collaboration brings together Daiichi Sankyo’s science and the multidisciplinary expertise of the LYSA- LYSARC and the CALYM research consortium to conduct clinical and translational research that will build upon the ongoing P-I study of valemetostat in patients with r/r non-Hodgkin lymphoma
- Valemetostat (DS-3201) is an EZH1/2 dual inhibitor currently in clinical development for several hematologic cancers
Ref: Businesswire | Image: YouTube
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com